Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Uterine Cervical Neoplasms 2Anus Neoplasms 2Neoplasms 1HIV Infections 1Benign Colorectal Neoplasm 1Anastomotic Leak 1Anal Canal Carcinoma 1Adenocarcinoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Doxorubicin 20Vincristine 17Zidovudine 13Cyclophosphamide 12Bleomycin 12Etoposide 10Rituximab 6Prednisone 6Interferon alpha-2 6Cytarabine 6Polymerase Chain Reaction 5Liposomes 5Filgrastim 5Dexamethasone 5Biopsy 5tecogalan 4sargramostim 4Specimen Handling 4Methotrexate 4Magnetic Resonance Spectroscopy 4Leucovorin 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4Fluorouracil 4Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Nivolumab 3interferon alfa-n1 2fludarabine phosphate 2fludarabine 2cabozantinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HIV Infections × Proctoscopy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡